Dr. Reddy’s Laboratories has launched the first OTC generic version of Pataday eye drops in the US. The FDA-approved product targets itchy eyes caused by allergens. Pataday recorded nearly $69.9 million in US sales over the last 52 weeks.
Source: Dr Reddy’s Press Release (NSE Exchange Fillings) | Published on Jan 14, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release of Dr Reddy’s (NSE Exchange Filings), following regulatory approval in the United States, the company has increased its presence in the Over-the-Counter (OTC) Eye Care Markets in America with the introduction of a new Allergy Relief Product; a generic equivalent of Extra Strength Pataday® Once-a-day Relief (OTC). The new product complements the company's existing Eye Care range and demonstrates the company's growing focus on expanding its presence within the Consumer Healthcare Categories.
Also read: BHEL Begins Supply of Traction Transformers for Vande Bharat
Launched the first OTC generic of Pataday in the US.
Product approved by the US Food and Drug Administration.
Targets temporary relief from allergy-related itchy eyes.
Expands Dr Reddy’s existing OTC eye-care range.
Also read: Pace Digitek Bags ₹375 Crore Solar EPC Order from Bondada
Olopatadine Hydrochloride Ophthalmic Solution USP 0.7% is now available in the US through Dr Reddy's after FDA approval. This product is the generic version of Extra Strength Pataday® Once Daily Relief, a popular brand used to treat eye allergies.
The eye drops are approved for temporary relief from itching from common allergens, including pollen, grass, ragweed, pet hair & dander. The eye drops come in a 2.5 mL size and will be sold in the US exclusively at retail pharmacies.
The expanded OTC Eye Care lineup includes previously offered Olopatadine 0.1% and 0.2% Fixed-Dose Combination products. This addition of a 0.7% Fixed-Dose Combination product will allow Dr. Reddy's to add to their current offerings and meet increasing consumer and retail demand for new options as they expand into many different doses of the allergy relief therapeutic class.
Adding additional SKU’s complements Dr. Reddy's strategy to be the leading provider of private label and generic products in the US Consumer Healthcare market, particularly for categories where there are consistent high volumes of demand for product.
As per reported retail sales information, the Pataday brand achieved roughly $69.9 million in US sales for the 52-week period ending 12/27/2025. This data provides an illustration of how extensive the allergy eye care marketplace is, as well as the potential business impact of creating a generic alternative.
Pataday is the name owned by Novartis AG. The introduction of a generic brand will contribute to increased competition in the over-the-counter (OTC) eye drop market, which is affected by factors such as price, distribution, and in-store visibility.
The U.S. market for OTC eye care products continues to be primarily driven by the seasonal nature of allergies, as well as continued consumer demand. Generic eye care products tend to be designed primarily to provide therapeutic equivalency with a focus on increased availability through a greater number of retail distribution channels. Dr Reddy's latest customer product launch is consistent with the industry-wide movement; it doesn’t change the regulatory structure or provide a new treatment approach.
Dr. Reddy’s share price stands at ₹1,186.50 per share on the BSE as of 14 January 2026 at 15:30 PM IST, down by 0.42%.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading